A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Helena J Janse van RensburgZhihui LiuGeoffrey Alan WatsonZachary W VeitchDaniel ShepshelovichAnna SpreaficoAlbiruni R Abdul RazakPhilippe L BedardLillian L SiuLori MinasianAaron Richard HansenPublished in: British journal of cancer (2023)
This tailored survey represents the first PRO tool developed specifically for assessing tolerability in the phase I oncology population. We provide recommendations for future work aimed at integrating this survey into clinical practice.